Glypvilo (Vildagliptin)

Glypvilo may be prescribed as initial therapy in patients who cannot tolerate metformin or when a DPP‑4 inhibitor is preferred, but treatment decisions should be individualized by a healthcare professional.

Yes, renal function should be evaluated before initiating Glypvilo, and dose adjustments may be necessary for patients with moderate to severe renal impairment.

Common adverse effects include upper respiratory tract infections, headache, dizziness, nausea, diarrhea, and mild skin rash.

Serious reactions can include severe allergic responses (anaphylaxis, angioedema), signs of pancreatitis (persistent abdominal pain), liver enzyme elevations, and severe hypoglycemia when combined with insulin or sulfonylureas.

Glypvilo can be taken with or without food; however, consistent administration with respect to meals may help maintain stable drug levels.

Yes, Glypvilo is often prescribed in combination with metformin to improve glycemic control when metformin alone does not achieve target glucose levels.

Regular monitoring of blood glucose, renal function, and liver enzymes is recommended, along with periodic assessment for signs of pancreatitis or hypersensitivity.

The safety of Glypvilo during pregnancy and lactation has not been fully established; it should only be used if the potential benefit justifies the potential risk, under medical supervision.

If a dose is missed, take it as soon as remembered unless it is near the time of the next scheduled dose. Do not double the dose; continue with the regular dosing schedule.

There are no specific dietary restrictions, but patients should maintain a balanced diet and avoid excessive alcohol, which can affect blood glucose control.

Glypvilo contains vildagliptin, which has a similar efficacy profile to other DPP‑4 inhibitors but may differ in dosing frequency, pharmacokinetics, and individual patient tolerability.